- Home
- CURR vs ALXO Comparison
CURR vs ALXO Comparison
Compare CURR & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURR
- ALXO
- Stock Information
- Founded
- CURR 2013
- ALXO 2015
- Country
- CURR Singapore
- ALXO United States
- Employees
- CURR N/A
- ALXO N/A
- Industry
- CURR Business Services
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- CURR Consumer Discretionary
- ALXO Health Care
- Exchange
- CURR Nasdaq
- ALXO Nasdaq
- Market Cap
- CURR 89.8M
- ALXO 76.5M
- IPO Year
- CURR N/A
- ALXO 2020
- Fundamental
- Price
- CURR $1.34
- ALXO $1.79
- Analyst Decision
- CURR
- ALXO Strong Buy
- Analyst Count
- CURR 0
- ALXO 5
- Target Price
- CURR N/A
- ALXO $13.25
- AVG Volume (30 Days)
- CURR 10.5K
- ALXO 1.1M
- Earning Date
- CURR 02-11-2025
- ALXO 11-07-2024
- Dividend Yield
- CURR N/A
- ALXO N/A
- EPS Growth
- CURR N/A
- ALXO N/A
- EPS
- CURR N/A
- ALXO N/A
- Revenue
- CURR $55,500,917.00
- ALXO N/A
- Revenue This Year
- CURR N/A
- ALXO N/A
- Revenue Next Year
- CURR N/A
- ALXO N/A
- P/E Ratio
- CURR N/A
- ALXO N/A
- Revenue Growth
- CURR N/A
- ALXO N/A
- 52 Week Low
- CURR $1.20
- ALXO $1.19
- 52 Week High
- CURR $5.74
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- CURR N/A
- ALXO 60.35
- Support Level
- CURR N/A
- ALXO $1.40
- Resistance Level
- CURR N/A
- ALXO $1.61
- Average True Range (ATR)
- CURR 0.00
- ALXO 0.18
- MACD
- CURR 0.00
- ALXO 0.02
- Stochastic Oscillator
- CURR 0.00
- ALXO 81.25
About CURR Currenc Group Inc. Ordinary Shares
Currenc Group Inc is a fintech banking platform for e-wallets, financial institutions and merchants worldwide, delivering frictionless interoperable real-time fund transfers and instant messaging.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.